| |
Denosumab
|
ZA
|
|---|
|
Risk factors
|
HR(95%CI)
|
P –value
|
HR(95%CI)
|
P - value
|
|
Age (y)
|
0.003*
| |
0.001*
|
|
≤60
|
1
| |
1
| |
|
> 60
|
3.13(1.02–1.68)
| |
4.72(2.36–7.17)
| |
|
Menopause age(y)
| |
0.440
| |
0.247
|
|
≤50
|
5.04(0.03–22.12)
| |
5.04(0.03–22.12)
| |
|
> 50
|
1
| |
1
| |
|
PHF
| |
0.002*
| |
0.005*
|
|
no
|
1
| |
1
| |
|
yes
|
21.34(5.23–49.12)
| |
36.75(2.39–74.32)
| |
|
FHF
| |
0.037*
| |
0.041*
|
|
no
|
1
| |
1
| |
|
yes
|
6.79(1.10–11.65)
| |
8.86(1.43–38.15)
| |
|
BMI(kg/m2)
| |
0.793
| |
0.219
|
|
≤19
|
3.76(0.66–31.32)
| |
5.36(0.19–44.61)
| |
|
> 19
|
1
| |
1
| |
-
*
Statistically significant values. SSEs: symptomatic skeletal events; ZA: zoledronic acid; PHF: personal history of fractures; FHF: family history of fractures; BMI: body mass index
